Non-squamous cell and non-small cell lung cancer
Conditions
Interventions
The combination therapy of nab-paclitaxel, carboplatin and bevacizumab
Sponsors
University of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Non-squamous cell and non-small cell lung cancer 2)Stage 3B or 4 3) Evaluable lesions 4) 20~74 years old 5) PS 0~1 6) No severe organ dysfunction and laboratory data fulfill the standards. 7) Three months and more survival is expected. 8) Informed consent 9) One regimen of EGFR-TKI or ALK-TKI is permitted.
Exclusion criteria
Exclusion criteria: 1) Brain metastasis accompnied by significant symptoms. 2) Hemoptysis 3) Allergy or hypersensitibity against the medicines in this trial or albumin. 4) Peripheral neuropathy (grade 2 or more) before the treatment. 5) Uncontrolled effusion. 6) Palliative radiation within 2 weeks. 7) Operation within 4 weeks. 8) Active double cancer 9) High body temperature (38 degrees Celsius and more). 10) Severe complications. 11) Anti-coagulation therapy 12) Pregnant woman 13) HBs antigen positive 14) The subjects whom the doctor excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressin free survival after the first line chemotherapy, the combination of nab-paclitaxel, carboplatin and bevacizumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival,progressin free survival after the maintenance therapy, response rate, and safety | — |
Countries
Japan
Contacts
Public ContactTamotsu Ishizuka
Faculty of Medical Sciences, University of Fukui Third Department of Internal Medicine
Outcome results
None listed